Article
Author(s):
Cabenuva (Cabotegravir-rilpivirine) is a 2-drug co-packaged product indicated as a complete regimen for the treatment of HIV-1 infection in adults.
Medication Pearl of the Day: Cabenuva (Cabotegravir-rilpivirine)
Indication: Cabenuva (Cabotegravir-rilpivirine) is a 2-drug co-packaged product of cabotegravir, a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), which is indicated as a complete regimen for the treatment of HIV-1 infection in adults.
Insight:
Source:
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children At Increased Risk